Skip to main content

Table 4 Phase 1 and early phase 1 bispecific antibodies (BiTE), antibody–drug conjugates (ADC), and monoclonal antibodies (MoAb) for RRMM, as of December 31, 2020, with study start date after January 1, 2019

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Target antigens Product name (NCT) Study sponsor Estimated enrollment Country
Bispecific antibodies (BiTE)     
BCMA × CD3 REGN5459 (NCT04083534) Regeneron 56 United States
BCMA × CD3 TNB-383B (NCT03933735) Teneobio 72 United States
BCMA × CD3 × albumin (“tri-specific”) HPN217 (NCT04184050) Harpoon 70 United States
BCMA × CD16a RO7297089 (NCT04434469) Genentech 80 Australia, Denmark, Norway
CD28/38 × CD3 SAR442257 (NCT04401020) Sanofi 57 United States
GPRC5D × CD3 and BCMA × CD3 Talquetamab and teclistamab (NCT04108195) Janssen 100 United States, Canada, Germany, the Netherlands, Spain
Antibody–drug conjugates (ADC)     
BCMA, monomethyl auristatin-F [59] GSK2857916 (belantamab mafodotin) (NCT03828292) GlaxoSmithKline 14 Japan
BCMA, maytansinoid CC-99712 (NCT04036461) Celgene 120 United States, Canada
BCMA, Shiga-like toxin-A subunit (engineered toxin bodies) [21] TAK-169 (NCT04017130) Millennium Takeda 102 United States
CD46, monomethyl auristatin-F [60] FOR46 (NCT03650491) Fortis 50 United States
Monoclonal antibodies (MoAb)     
CD38 SAR442085 (NCT04000282) Sanofi 78 United States, France, Spain
CD47 AO-176 (NCT04445701) Arch Oncology 102 United States
IL-18 AEVI-007 (NCT04671251) Aevi/Cerecor 30 United States